RESULTS REVIEW 2QFY14 31 OCT 2013



INSTITUTIONAL RESEARCH

BUY

INDUSTRY		PH	ARMA
CMP (as on 30 (Oct 201	3)	Rs 902
Target Price			Rs 994
Nifty			6,252
Sensex			21,034
KEY STOCK DATA			
Bloomberg /Reut	ers	LPC IN/L	UPN.BO
No. of Shares (mr	ı)		448
MCap (Rs bn) / (\$	mn)	40	4/6,596
6m avg traded va	lue (Rs ı	nn)	983
STOCK PERFORM	ANCE (9	%)	
52 Week high / lo	w	Rs 94	6 / 557
	3M	6M	12M
Absolute (%)	7.4	28.4	59.4
Relative (%)	(1.3)	20.6	45.3
SHAREHOLDING	PATTER	N (%)	
Promoters			46.78
FIs & Local MFs			12.07
FIIs			31.45
Public & Others			9.70
Source : BSE			

Meeta Shetty, CFA meeta.shetty@hdfcsec.com +91-22-6171-7338

In line quarter, outlook strong

Lupin Ltd (LPC) results were in line with expectations. Domestic formulations growth at 9% was ahead of our expectations (5%). US sales were a disappointment at US\$167mn, however management indicated to post ~US\$775mn (in line with our expectations) for the fiscal. Gross margins expanded by ~800bps due to currency benefits, however ~200bps increase in employee spend as well as other expenses restricted EBIDTA margins at 24.7%. Higher tax rate at 38%, resulted to Adj PAT of Rs 4.04b (up 35%), in spite of higher other income of Rs0.8bn.

Main concern for LPC in recent times has been increasing competition in its US branded portfolio and gTricor, but we believe interesting opportunities lined up in 2HFY14 and gradual ramp up in the OC's portfolio would more than offset for the weakness. With most visible pipeline for the US and a strong product portfolio at homeland, we firmly believe LPC is poised for strong 20/25% CAGR on its revenue/PAT for the coming years. Delays in US approvals remain key risk to our call.

FINANCIAL SUMMARY

US – 2H to be sanguine : Though LPC has posted lower than expected US revenues, management indicated of ~US\$775mn revenues for the fiscal. Lower than expected revenues were due to expiration of Aero chamber deal with Forest and lower sales in anti-infective products. Limited competition in 2HFY14 would keep the momentum strong. We largely maintain our estimates at US\$773/946mn in FY14/15E for US.

- **Fierce gross margin expansion :** LPC's gross margins expanded by ~800bps YoY at 68% driven by currency benefit on both operational as well as translation front. However, if currency remains at current levels, we expect gross margins to subside back to its run-rate of 62-63%.
- Domestic formulations growth to taper : Owing to high base of 2HFY13 and weak 1HFY14, management has lowered its growth guidance for the segment from 15% to 10-11%.
- We remain positive on the stock and maintain Buy with a revised target price of Rs 994 at 22x its FY15E EPS of Rs 45.2 (earlier Rs 42.8).


Year Ending March (Rs mn)	2QFY14	2QFY13	YoY (%)	1QFY14	QoQ (%)	FY12	FY13	FY14E	FY15E
Net Sales	26,315	22,393	17.5	24,207	8.7	68,204	93,694	111,168	134,584
EBITDA	6,596	5,159	27.8	5,895	11.9	14,447	22,700	27,009	33,377
APAT	4,062	2,905	39.8	4,011	1.3	8,745	13,025	17,573	20,225
Diluted EPS (Rs)	9.1	6.5	39.2	9.0	0.8	19.6	29.1	39.3	45.2
P/E (x)	-	-	-	-	-	52.2	31.0	23.0	20.0
EV / EBITDA (x)	-	-	-	-	-	28.7	18.9	15.0	11.9
RoE (%)	-	-	-	-	-	23.8	28.5	29.5	26.8

Source: Company, HDFC sec Inst Research

HDFC securities Institutional Research is also available on Bloomberg HSLB <GO> & Thomson Reuters



Business highlights




Source: Company, HDFC sec Inst Research

US revenues [43% of sales]

- US revenues were at Rs 10.3bn, up 32% in rupee terms and ~16% in dollar terms (USD 167mn).
- LPC's deal with Forest labs to promote Aero chambers expired last quarter, which partially led to lower than expected US revenues.
- Branded generics contribution came down significantly to 11% during the quarter from ~20% levels in earlier quarter.
- Generic revenues were ~USD 150mn, due to increased competition on Tricor. Lower off take in anti-infective segment also kept the revenues low.
- We expect limited competition opportunities like Niaspan, Trizivir and Trilipix to materialize in 2HFY14.
- We tone down our expectation for OC's to US\$ 40/89mn from US\$55/114mn owing to intense competition. Overall we expect LPC to post US\$ 773/946mn revenues for US segment.

Manages a good show



Source: Company, HDFC sec Inst Research


Domestic revenues [23% of sales]

- Domestic formulations posted growth of 9% during the quarter at Rs 6.6bn.
- LPC has not given into the demands of wholesaler/retailer for higher margins and this could lead to some more restriction in growth for coming quarters.
- Owing to high base of 2HFY13, management has further revised its guidance from 15% to 10-11% for the segment in FY14E. (Last quarter management revised it from 18% to 15%).
- However, we expect revival in FY15E, given the strong product portfolio and proven track record of consistently outperforming IPM.
- We revise our growth for FY14 from 13.4% to 10.5% and maintain 18.5% for FY15E.



INSTITUTIONAL RESEARCH

I'rom de-growth to continue



Source: Company, HDFC sec Inst Research

Japan revenues [12% of sales]

- Japan posted de-growth of 6% during the quarter in rupee terms at Rs 3.1bn.
- I'rom revenues degrew by 11% for the quarter resulting in weak Japan sales. I'rom constitutes ~30% to the region.
- l'rom contract manufacturing segment (30% contribution to sales) continued to see lower off take resulting in de-growth.
- LPC expects l'rom sales to remain under pressure for the fiscal and expects it to de-grow by 7-8%. Hence we revise ouR l'rom growth estimates from 11% growth to 7% de-growth.
- Kyowa maintained its growth at 9% for the quarter, we expect it to grow at 12% CAGR over FY13-15E.
- Overall, including both subsidiaries, We expect Japan to post 7% growth (earlier 12%) in rupee terms.

Key highlights of concall

- LPC expects Niaspan to be a limited competition opportunity in spite of 7/8 filers for the product. Expects to enter the market in Teva's exclusivity, ending in Mar-14
- Management expects to regain its revenues loss on Antara through its low dosage launch of 90mg Antara.
- Tricor still has 30% market share post Maylan entry.
 Price has although seen some correction.
- For US, Lupin plans to enter inhalation, derma and controlled substance areas in the coming future.
- Antara market share Lupin at 35%, Lupin AG at 40%, Mylan at 25%
- Antara Apotex yet to launch the product.
- Other income includes forex gain of Rs 714mn (Reported Other income at Rs 814mn).
- However, overall forex impact in PAT at Rs 42mn.



QUARTERLY FINANCIALS SNAPSHOT

(Rs mn)	2QFY14	2QFY13	YoY (%)	1QFY14	QoQ (%)
Net Sales	26,315	22,393	17.5	24,207	8.7
Material Expenses	8,413	8,898	(5.4)	8,748	(3.8)
Employee Expenses	3,682	3,000	22.7	3,281	12.2
Other Operating Expenses	5,816	5,014	16.0	4,882	19.1
Research and Development expenses	2,172	935	132.3	1,956	11.0
Operating Profits	6,232	4,545	37.1	5,340	16.7
Other Operating Income	364	614	(40.7)	555	(34.4)
EBITDA	6,596	5,159	27.8	5,895	11.9
EBITDA (excl one-offs)	6,596	5,159	27.8	5,895	11.9
Interest Cost	49	101	(51.5)	54	(10.1)
Depreciation	606	690	(12.2)	624	(2.9)
Other Income	857	43	1,882.9	1,009	(15.1)
PBT	6,798	4,412	54.1	6,226	9.2
Tax	2,582	1,438	79.5	2,172	18.9
RPAT	4,216	2,974	41.8	4,055	4.0
Minority interest	(111)	(69)	60.9	(44)	152.3
Reported PAT	4,062	2,905	39.8	4,011	1.3
E/o (adj for tax)	(16)	85		-	
APAT	4,045	2,989	35.3	4,011	0.9

Source: Company, HDFC sec Inst Research

MARGIN ANALYSIS

Margin Analysis	2QFY14	2QFY13	YoY (bps)	1QFY14	QoQ (bps)
Material Expenses as % of Net Sales	32	40	(776.5)	36	(416.6)
Employee Expenses as % of Net Sales	14	13	59.4	14	43.7
Other Operating Expenses as % of Net Sales	22	22	(29.2)	20	193.5
Operating Margin (%)	24	20	338.5	22	162.1
EBITDA Margin (%)	25	22	229.8	24	91.5
Adj EBITDA Margin (%)	25	22	229.8	24	91.5
APAT Margin (%)	15	13	217.0	16	(103.4)

Source: Company, HDFC sec Inst Research



SALES MIX

(Rs mn)	2QFY14	2QFY13	YoY (%)	1QFY14	QoQ (%)	FY12	FY13	FY14	FY15
Formulations	23,942.0	20,001	20	21,778	10	60,163	84,447	101,059	123,492
- Domestic Formulations	6,635.0	6,064	9	5,894	13	19,374	23,840	26,336	31,214
- US formulaitons	10,349.0	7,818	32	10,350	(0)	24,230	36,830	47,183	59,574
- US generics (Inc IP)	9,257	6,254	48	9,200	1	17,203	29,096	39,702	51,574
- US Branded	1,092	1,564	(30)	1,150	(5)	7,027	7,734	7,481	8,000
- Japan formulations	3,098.0	3,301	(6)	2,923	6	8,577	13,068	13,926	15,704
- Europe formulaitons	741.0	626	18	644	15	1,975	2,356	2,718	2,990
- Other EM formulations	3,119.0	2,192	42	1,967	59	6,007	8,353	10,895	14,011
API	2,392.0	2,392	0	2,429	(2)	8,885	9,498	10,110	11,092
Revenues	26,334.0	22,393	18	24,207	9	69,048	93,945	111,168	134,584

Source: Company, HDFC sec Inst Research

CHANGE IN ESTIMATES

(Bc.mm)	Revise	d	Old		
(Rs mn)	FY14E	FY15E	FY14E	FY15E	
Net Sales	111,168	134,584	115,750	134,284	
EBIDTA	27,009	33,377	28,778	32,897	
EBIDTA %	23.9	24.4	24.5	24.1	
АРАТ	17,573	20,225	16,452	19,105	

Source: HDFC sec Inst Research

INCOME STATEMENT

Year ending March (Rs mn)	FY11	FY12	FY13	FY14E	FY15E
Net Sales	56,478	68,204	93,694	111,168	134,584
Growth (%)	19.1	20.8	39.6	16.7	21.1
Material Expenses	22,379	26,039	35,480	40,021	50,469
Employee Expenses	7,677	9,695	12,488	15,235	18,587
Other Operating Expenses	16,353	20,648	25,745	30,661	34,228
Operating Profits	10,068	11,822	19,981	25,252	31,299
Operating Profit Margin (%)	17.6	17.0	19.3	21.1	21.7
Other Operating Income	1,712	2,626	1,797	1,758	2,078
EBIDTA	11,780	14,447	21,778	27,009	33,377
EBIDTA (%)	20.2	20.4	23.5	23.9	24.4
EBIDTA Growth (%)	19.7	22.6	57.1	19.0	23.6
Other Income	222	143	279	2,317	739
Depreciation	1,712	2,275	3,322	2,806	3,641
EBIT	10,290	12,315	18,734	26,520	30,475
Interest	345	355	410	354	359
Forex gain/loss	-	-	-	-	-
PBT	9,945	11,961	18,324	26,167	30,116
Тах	1,169	3,086	5,842	8,243	9,487
PAT	8,776	8,875	12,482	17,924	20,629
Minority Interest	(168)	(199)	(263)	(351)	(404)
EO items (net of tax)	-	-	-	-	-
АРАТ	8,048	7,717	13,025	17,573	20,225
APAT Growth (%)	19.9	(4.1)	68.8	34.9	15.1
EPS	18.0	17.3	29.1	39.3	45.2
EPS Growth (%)	19.9	(4.1)	68.8	34.9	15.1

Source: Company, HDFC sec Inst Research

Year ending March (Rs mn)	FY11	FY12	FY13	FY14E	FY15E
SOURCES OF FUNDS					
Share Capital	892	893	895	895	895
Reserves	31,918	39,236	51,147	66,083	83,145
Total Shareholders' Funds	32,811	40,129	52,042	66,978	84,040
Minority Interest	515	723	595	946	1,350
Long Term Debt	3,713	5,921	4,377	2,471	971
Short Term Debt	7,911	10,470	7,268	7,632	8,013
Total Debt	11,624	16,391	11,645	10,102	8,984
Deferred Taxes	1,792	1,910	2,337	2,468	2,618
Long Term Provisions & Others	933	1,528	1,626	1,417	1,588
TOTAL SOURCES OF FUNDS	47,675	60,681	68,244	81,911	98,580
APPLICATION OF FUNDS					
Net Block	17,313	22,457	24,929	27,119	28,725
CWIP	4,904	4,437	3,107	2,747	3,021
Goodwill	3,255	5,040	5,073	5,073	5,073
Investments, LT Loans & Advances	3,601	4,465	4,599	4,413	4,498
Inventories	12,000	17,327	19,489	25,888	31,341
Debtors	12,556	17,800	21,870	25,279	31,341
Cash & Equivalents	4,202	4,025	4,349	8,697	14,545
ST Loans & Advances, Others	3,412	4,272	5,723	6,296	6,925
Total Current Assets	32,170	43,423	51,431	66,160	84,153
Creditors	9,930	13,793	15,431	18,640	21,432
Other Current Liabilities & Provns	3,639	5,349	5,464	4,962	5,458
Total Current Liabilities	13,569	19,142	20,895	23,601	26,890
Net Current Assets	18,601	24,282	30,536	42,559	57,263
Misc Expenses & Others	-	-	-	-	-
TOTAL APPLICATION OF FUNDS	47,675	60,681	68,244	81,911	98,580

Source: Company, HDFC sec Inst Research

INSTITUTIONAL RESEARCH

CASH FLOW

(Rs mn)	FY11	FY12	FY13P	FY14E	FY15E
Reported PAT	8,776	8,875	13,404	17,924	20,629
Non-operating & EO items	(193)	59	(24)	(1,587)	(506)
PAT from Operations	8,583	8,934	13,380	16,337	20,123
Interest expenses	345	355	410	354	359
Depreciation	1,712	2,275	3,322	2,806	3,641
Working Capital Change	(552)	(5,858)	(5,931)	(7,675)	(8 <i>,</i> 856)
OPERATING CASH FLOW (a)	10,087	5,706	11,181	11,822	15,268
Capex	(4,544)	(8,737)	(4,497)	(4,636)	(5,521)
Free cash flow (FCF)	5,543	(3,031)	6,685	7,186	9,747
Investments	(3,142)	(864)	(133)	186	(85)
INVESTING CASH FLOW (b)	(7,686)	(9,600)	(4,630)	(4,451)	(5 <i>,</i> 606)
Share capital Issuance	3	1	2	0	0
Debt Issuance	225	4,767	(4,746)	(1,543)	(1,118)
Other long term lia	1,283	1,047	1,012	(78)	321
Interest expenses	(345)	(355)	(410)	(354)	(359)
Dividend	(1,575)	(1,684)	(2,109)	(2,636)	(3,163)
FINANCING CASH FLOW (c)	(408)	3,776	(6,251)	(4,610)	(4,320)
NET CASH FLOW (a+b+c)	1,993	(118)	300	2,761	5,342
Non-operating and EO items	193	(59)	24	1,587	506
Closing Cash & Equivalents	4,202	4,025	4,349	8,697	14,545

Source: Company, HDFC sec Inst Research

KEY RATIOS


	FY11	FY12	FY13P	FY14E	FY15E
PROFITABILITY (%)					
GPM	60.8	62.6	62.5	64.0	62.5
EBITDA Margin	20.2	20.4	23.5	23.9	24.4
APAT Margin	14.3	11.3	13.9	15.8	15.0
RoE	29.4	23.8	28.5	29.5	26.8
ROIC	20.5	15.8	21.0	24.3	24.4
RoCE	18.4	15.8	23.3	27.2	26.4
EFFICIENCY	21.0	16.5	20.8	23.7	22.7
Tax Rate (%)	11.8	25.8	30.4	31.5	31.5
Asset Turnover (x)	0.9	0.9	1.1	1.1	1.1
Inventory (days)	69.4	76.9	71.2	74.5	77.6
Debtors (days)	76.2	79.6	76.8	77.4	76.8
Payables (days)	138.9	166.3	150.3	155.4	144.9
Cash Conversion Cycle (days)	6.7	-9.8	-2.3	-3.5	9.5
Debt/EBITDA (x)	1.0	1.1	0.5	0.4	0.3
Net D/E	0.2	0.3	0.1	0.0	-0.1
Interest Coverage	25.8	25.2	32.7	50.4	57.0
PER SHARE DATA					
EPS (Rs/sh)	18.0	17.3	29.1	39.3	45.2
Core EPS	23.5	25.0	37.4	46.3	54.2
CEPS (Rs/sh)	3.0	3.2	4.0	5.0	6.0
DPS (Rs/sh)	73.5	89.8	116.3	149.7	187.8
BV (Rs/sh)					
VALUATION					
P/E	50.0	52.2	31.0	23.0	20.0
P/BV	12.3	10.0	7.8	6.0	4.8
EV/EBITDA	34.8	28.7	18.9	15.0	11.9
OCF/EV (%)	2.5	1.4	2.7	2.9	3.8
FCF/EV (%)	1.3	(0.8)	1.5	1.7	2.4
FCFE/EV (%)	1.4	(0.7)	1.6	1.8	2.4
Dividend Yield (%)	0.3	0.4	0.4	0.6	0.7

Source: Company, HDFC sec Inst Research

HDFC securities

INSTITUTIONAL RESEARCH

RECOMMENDATION HISTORY



Date	СМР	Reco	Target
5-Jul-13	835	BUY	893
9-Aug-13	801	BUY	893
12-Sep-13	866	BUY	941
31-Oct-13	902	BUY	994

Rating Definitions

BUY : Where the stock is expected to deliver more than 10% returns over the next 12 month period

NEUTRAL : Where the stock is expected to deliver (-)10% to 10% returns over the next 12 month period

SELL : Where the stock is expected to deliver less than (-)10% returns over the next 12 month period

Disclaimer: This report has been prepared by HDFC Securities Ltd and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HDFC Securities Ltd or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of HDFC Securities Ltd .

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk.

It should not be considered to be taken as an offer to sell or a solicitation to buy any security. HDFC Securities Ltd may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HDFC Securities and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HDFC Securities Ltd, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HDFC Securities Ltd and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organisations described in this report.

HDFC securities

Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel,

Mumbai - 400 013

Board : +91-22-6171 7330

www.hdfcsec.com